Notice2022-11631
TG Therapeutics, Inc.; Withdrawal of Approval of New Drug Application for UKONIQ (Umbralisib Tosylate) Tablets, Equivalent to 200 Milligrams Base
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 31, 2022
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA or Agency) is withdrawing approval of the new drug application (NDA) for UKONIQ (umbralisib tosylate) Tablets, equivalent to (EQ) 200 milligrams (mg) Base, held by TG Therapeutics, Inc., 3020 Carrington Mill Blvd., Morrisville, NC 27560. TG Therapeutics, Inc. (TGT) has voluntarily requested that FDA withdraw approval of this application and has waived its opportunity for a hearing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 104 (Tuesday, May 31, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 104 (Tuesday, May 31, 2022)]
[Notices]
[Page 32425]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-11631]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-N-0887]
TG Therapeutics, Inc.; Withdrawal of Approval of New Drug
Application for UKONIQ (Umbralisib Tosylate) Tablets, Equivalent to 200
Milligrams Base
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is
withdrawing approval of the new drug application (NDA) for UKONIQ
(umbralisib tosylate) Tablets, equivalent to (EQ) 200 milligrams (mg)
Base, held by TG Therapeutics, Inc., 3020 Carrington Mill Blvd.,
Morrisville, NC 27560. TG Therapeutics, Inc. (TGT) has voluntarily
requested that FDA withdraw approval of this application and has waived
its opportunity for a hearing.
DATES: Approval is withdrawn as of May 31, 2022.
FOR FURTHER INFORMATION CONTACT: Kimberly Lehrfeld, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993-0002, 301-
796-3137, <a href="/cdn-cgi/l/email-protection#a5eeccc8c7c0d7c9dc8be9c0cdd7c3c0c9c1e5c3c1c48bcdcdd68bc2cad3"><span class="__cf_email__" data-cfemail="3e7557535c5b4c524710725b564c585b525a7e585a5f1056564d10595148">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: On February 5, 2021, FDA approved NDA 213176
for UKONIQ (umbralisib tosylate) Tablets, EQ 200 mg base, for the
treatment of adult patients with: (1) Relapsed or refractory marginal
zone lymphoma (MZL) who have received at least one prior anti-CD20-
based regimen and (2) relapsed or refractory follicular lymphoma (FL)
who have received at least three prior lines of systemic therapy, under
the Agency's accelerated approval regulations, 21 CFR part 314, subpart
H. The accelerated approval of UKONIQ (umbralisib tosylate) Tablets, EQ
200 mg base, for MZL and FL included required postmarketing trials
intended to verify the clinical benefit of UKONIQ.
On February 3, 2022, FDA issued a Drug Safety Communication about a
possible increased risk of death with UKONIQ (umbralisib tosylate)
Tablets, EQ 200 mg base. FDA's initial review of data from a phase 3,
randomized, controlled clinical trial in patients with chronic
lymphocytic leukemia (CLL) who were administered UKONIQ (umbralisib
tosylate) Tablets, EQ 200 mg base, in combination with a monoclonal
antibody drug compared to the control arm showed a possible increased
risk of death in patients receiving the combination of UKONIQ
(umbralisib tosylate) Tablets, EQ 200 mg base, and the monoclonal
antibody (UNITY-CLL trial). Those patients receiving the combination
also experienced more serious adverse events than those in the control
arm. FDA considered the data from the UNITY-CLL trial conducted in
patients with CLL to have implications for UKONIQ's approved uses for
MZL and FL.
On March 10, 2022 (87 FR 13736), FDA published the Federal Register
notice ``Oncologic Drugs Advisory Committee; Notice of Meeting;
Establishment of a Public Docket; Request for Comments,'' announcing
that UKONIQ (umbralisib tosylate) Tablets, EQ 200 mg base, would be
discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting
scheduled for April 22, 2022.
FDA met with TGT on April 14, 2022, to discuss voluntary withdrawal
of UKONIQ (umbralisib tosylate) Tablets, EQ 200 mg base, pursuant to
Sec. 314.150(d) (21 CFR 314.150(d)) due to the decrement in overall
survival and increased serious adverse events observed with UKONIQ
(umbralisib tosylate) Tablets, EQ 200 mg base, in the UNITY-CLL trial.
FDA recommended the applicant voluntarily request withdrawal of
approval of UKONIQ (umbralisib tosylate) Tablets, EQ 200 mg base, for
the follicular lymphoma and marginal zone lymphoma indications pursuant
to Sec. 314.150(d) and requested TGT waive its opportunity for a
hearing.
On April 15, 2022, TGT submitted a letter asking FDA to withdraw
approval of NDA 213176 for UKONIQ (umbralisib tosylate) Tablets, EQ 200
mg base, pursuant to Sec. 314.150(d) and waiving its opportunity for a
hearing. On April 18, 2022, FDA acknowledged TGT's request for
withdrawal of approval of the NDA and waiver of its opportunity for a
hearing. FDA also cancelled the ODAC meeting scheduled for April 22,
2022, because the meeting was unnecessary considering the applicant's
withdrawal request.
For the reasons discussed above, and in accordance with the
applicant's request, approval of NDA 213176 for UKONIQ (umbralisib
tosylate) Tablets, EQ 200 mg base, and all amendments and supplements
thereto, is withdrawn under Sec. 314.150(d). Distribution of UKONIQ
(umbralisib tosylate) Tablets, EQ 200 mg base, into interstate commerce
without an approved application is illegal and subject to regulatory
action (see sections 505(a) and 301(d) of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 355(a) and 331(d)).
Dated: May 25, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-11631 Filed 5-27-22; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on May 31, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.